A comparison of the SMAD2 mutations with clinical characteristics of cancers did not reveal an association of mutations with cancer stages, but p.S464Ter showed a trend toward decreased OS of patients with the mutations (Figure 5D) in pan-cancer and in the individual cancers with >1 p.S464Ter occurrence in informative samples. Here, SMAD2 is linked to cancer.